Skip Navigation


Annals of Oncology Advance Access originally published online on March 8, 2006
Annals of Oncology 2006 17(6):962-967; doi:10.1093/annonc/mdl037
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/6/962    most recent
mdl037v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Francoual, M.
Right arrow Articles by Milano, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Francoual, M.
Right arrow Articles by Milano, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

EGFR in colorectal cancer: more than a simple receptor

M. Francoual1, M.-C. Etienne-Grimaldi1, J.-L. Formento1, D. Benchimol2, A. Bourgeon2, M. Chazal3, C. Letoublon4, T. André5, N. Gilly6, J.-R. Delpero7, P. Lasser8, J.-P. Spano9 and G. Milano1,*

1 Centre Antoine-Lacassagne, Nice; 2 Hôpital l'Archet, Nice; 3 Centre Médical Valbrise, Nice; 4 CHU de Grenoble, Grenoble; 5 Hôpital Tenon, Paris; 6 Centre Hospitalier Lyon-Sud, Pierre-Bénite; 7 Institut Paoli-Calmettes, Marseille; 8 Institut Gustave Roussy, Villejuif; 9 GH Pitié-Salpétrière, Paris, France

* Correspondence to: Dr G. Milano, Oncopharmacology Unit, Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189 Nice Cedex 2, France. Tel: +33. (4).92.03.15.53; Fax: +33. (4).93.81.71.31; E-mail: gerard.milano{at}nice.fnclcc.fr

Background: Advances in the understanding of tumor biology have led to the development of targeted therapies allowing progress in colorectal cancer treatment. One of the most promising targets is the epidermal growth factor receptor (EGFR).

Method: The presence and distribution of high- and low-affinity EGFR was investigated retrospectively in a group of 82 colorectal cancer samples (43 normal colon–colon cancer paired samples) using a specific ligand binding assay (Scatchard Analysis).

Findings: A large majority of tumor samples exhibited one class of high-affinity binding sites (78%). Eighteen cases (22%) exhibited both high- and low-affinity binding sites. A wide interpatient variability was observed for the site number, with physiologically-relevant high-affinity sites ranging from 7 to 310 fmol/mg protein in tumors and from 6 to 313 fmol/mg protein in normal mucosa. A significant positive correlation was demonstrated between tumor and normal mucosa for the high-affinity Kd values and for the number of high-affinity sites, suggesting a common regulation for both tumor and normal tissue.

Interpretation: These observations (i) could explain recently-reported clinically-active EGFR targeting in colorectal tumors apparently negative for EGFR, and (ii) may offer a plausible explanation for the link observed between toxicity in normal tissue (cutaneous rash) and clinical outcome of patients treated with anti-EGFR drugs. Present data extends our understanding of EGFR identity in colorectal cancer which could be useful in reconsidering the predictive tools for the identification of tumors putatively responsive to EGFR targeted therapy.

Key words: colorectal cancer, EGFR, epidermal growth factor receptor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
J Natl Cancer Inst, October 7, 2009; 101(19): 1308 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Milano, M.-C. Etienne-Grimaldi, L. Dahan, M. Francoual, J.-P. Spano, D. Benchimol, M. Chazal, C. Letoublon, T. Andre, F.-N. Gilly, et al.
Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer
Ann. Onc., December 1, 2008; 19(12): 2033 - 2038.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, et al.
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
N. Engl. J. Med., October 23, 2008; 359(17): 1757 - 1765.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Graziano, A. Ruzzo, F. Loupakis, E. Canestrari, D. Santini, V. Catalano, R. Bisonni, U. Torresi, I. Floriani, G. Schiavon, et al.
Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer
J. Clin. Oncol., March 20, 2008; 26(9): 1427 - 1434.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Lievre, J.-B. Bachet, V. Boige, A. Cayre, D. Le Corre, E. Buc, M. Ychou, O. Bouche, B. Landi, C. Louvet, et al.
KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
J. Clin. Oncol., January 20, 2008; 26(3): 374 - 379.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M-C Etienne-Grimaldi, A Cayre, F Penault-Llorca, M Francoual, J-L Formento, D Benchimol, A Bourgeon, and G Milano
EGFR expression in colon cancer: a break in the clouds
Ann. Onc., December 1, 2006; 17(12): 1850 - 1851.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.